TABLE 7.
Clinical trials of intensive-phase intravenous antibiotics in severe melioidosis
| Reference | Regimen (dose, mg/kg/day) | Duration (days) | No. of patients
|
Outcome measures (%)
|
||
|---|---|---|---|---|---|---|
| Enrolled | Culture confirmed | Treatment failure | Mortality | |||
| 473 | Ceftazidime (120) vs chloramphenicol (100), doxycycline (4), and TMP-SMX (10/50) | At least 7 | 161 | 34 vs 31 | 37 vs 74 | |
| 400 | Ceftazidime (100) and TMP-SMX (8/40) vs chloramphenicol (100), doxycycline (4), and TMP-SMX (8/40) | 10-14 | 136 | 27 vs 34 | 18.5 vs 47 | |
| 419 | Ceftazidime (120) vs amoxicillin-clavulanate (120/40) | At least 7 | 379 | 106 vs 105 | 39 vs 51 | 47 vs 47 |
| 383 | Ceftazidime (120) vs imipenem (50) | At least 10 | 296 | 106 vs 108 | 41 vs 20 | 38 vs 36 |
| 423 | Ceftazidime (25) and co-trimoxazole (8/40) vs cefoperazone-sulbactam (100) and co-trimoxazole (8/40) | 84 | 20 vs 20 | 21 vs 16 | ||
| 90 | Ceftazidime (100) and TMP-SMX (8/40) vs Cefoperazone-sulbactam (25/25) | 14 | 219 | 51 vs 51 | 14 vs 18 | |
| W. Chierakul et al., unpublished data | Ceftazidime (120) vs ceftazidime (120) and TMP-SMX (10/50) | 10 days | 449 | 118 vs 123 | No significant difference | |